Skip to main content
Premium Trial:

Request an Annual Quote

William Moffitt, Jay Lichter, Dereck Tatman, Murlai Prahalad, Pete De Spain, Istvan Merchenthaler, James Greenwood, Carl Feldbaum, Steve Lombardi


William Moffitt has been named president and chief executive officer of Nanosphere, a Northbrook, Ill.-based developer of a molecular diagnostics platform. Moffitt most recently served as president and CEO of I-Stat, a point-of-care diagnostics manufacturer. The company was purchased by Abbott Laboratories in 2003. Previous to his term at I-Stat, Moffitt held several executive positions at Deerfield, Ill.-based Baxter Healthcare.

Jay Lichter, who was executive vice president of business development at Sequenom, has left the company, an outside company spokesperson confirmed last week. Dereck Tatman and Murlai Prahalad, who serve as directors of business development at Sequenom, have assumed the duties held by Lichter. Also Pete De Spain, manager of corporate communications at Sequenom, has left the company, and is now manager of corporate communications at Anadys Pharmaceuticals, of San Diego.

Istvan Merchenthaler has been appointed chief medical officer at Phylogeny, the company said last week. Merchenthaler will oversee functional genomics studies for Phylogeny’s pharmaceutical and biotech clients, with an emphasis on understanding gene expression patterns in the central nervous system, the company said. Prior to joining Phylogeny, Merchenthaler was employed by Wyeth Research, where he served as a distinguished research scientist and director of functional morphology for the company’s Women’s Health Research Institute for 10 years.

Congressman James Greenwood (R-Pa.) was named the next president of the Biotechnology Industry Organization last week. Greenwood has represented the Eighth District of Pennsylvania in the US House of Representatives since 1993. He previously served in the Pennsylvania House and Senate, and since 2001, he has served as chairman of the Energy and Commerce Subcommittee on Oversight and Investigations. He will be replacing Carl Feldbaum, who has headed BIO since its establishment in July 1993.

Steve Lombardi has been named as a non-executive director of Paris-based molecular diagnostics firm IntegraGen. Lombardi is currently senior vice president of corporate development at Affymetrix.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.